GSM5359431
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.330
- BILE_ACID_METABOLISM+0.320
- PEROXISOME+0.230
- SPERMATOGENESIS+0.200
- E2F_TARGETS+0.190
- FATTY_ACID_METABOLISM+0.150
- XENOBIOTIC_METABOLISM+0.130
- ADIPOGENESIS+0.090
- OXIDATIVE_PHOSPHORYLATION+0.060
- KRAS_SIGNALING_DN+0.040
Top 10 suppressed
- MYC_TARGETS_V2-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.470
- MYC_TARGETS_V1-0.460
- TNFA_SIGNALING_VIA_NFKB-0.420
- NOTCH_SIGNALING-0.390
- TGF_BETA_SIGNALING-0.390
- WNT_BETA_CATENIN_SIGNALING-0.390
- HYPOXIA-0.370
- IL6_JAK_STAT3_SIGNALING-0.340
- MTORC1_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.847 |
| 2 | 66326_S124 | — | cohortA1 | 0.820 |
| 3 | SRR664854 | GTEX | — | 0.813 |
| 4 | TCGA-XF-A8HC-01A-11R-A36F-07 | — | — | 0.801 |
| 5 | SRR8943038 | — | — | 0.800 |
| 6 | X32c1a1c5.08f3.4980.bdb3.37c652822988 | — | cohortA1 | 0.799 |
| 7 | R70 | — | — | 0.794 |
| 8 | SRR12202427 | — | — | 0.793 |
| 9 | TCGA-E7-A7PW-01A-11R-A352-07 | — | — | 0.781 |
| 10 | SRR2700736 | — | — | 0.776 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |